



## ACKNOWLEDGEMENTS

The Chairmen of the Meeting would like to thank

### Major Sponsors



Leaders in healthcare. Innovators in life.




### Mascia Brunelli



THE NEW STANDARD FOR PLATELET DIAGNOSTICS



## SIEMENS



## 6<sup>th</sup> International Meeting

# ADP 2010 Platelet Receptors: from Basic Science to Clinical Practice

### Chairmen:

Marco Cattaneo (Milano, Italy)  
Christian Gachet (Strasbourg, France)

## PROGRAM

### VILLA CAGNOLA

Gazzada Schianno (VA), Italy

September 2-4, 2010

Under the auspices of:



Associazione per la Lotta alla Trombosi



Società Italiana  
per lo Studio dell'Emostasi  
e della Trombosi



Gruppo di studio Associazioni, Trombosi, Biologia Vascolare



## C.M.E. ACCREDITATION



## PROGRAM

Thursday, September 2, 2010

**14:15-15:15** **SESSION 1**  
**"INTRODUCTORY LECTURES"**

Chairpersons: *Marco Cattaneo (Milano, Italy)*  
*Christian Gachet (Strasbourg, France)*

14:15-14:45 **Update on P2 receptors and their inhibitors**  
*Kenneth A. Jacobson (Washington, USA)*

14:45-15:15 **Platelet formation**  
*Alessandra Balduini (Pavia, Italy)*

15:15-15:45 Coffee Break ☕

**15:45-18:15** **SESSION 2**  
**"PLATELETS: PHYSIOLOGY AND PATHOLOGY"**

Chairpersons: *Carlo Balduini (Pavia, Italy)*  
*Luigi De Marco (Aviano, Italy)*

15:45-16:15 **Regulation and function of phosphatidylinositol 3-kinase $\beta$  in platelet integrin signaling**  
*Mauro Torti (Pavia, Italy)*

16:15-16:45 **Inherited defects that affect signaling pathways of platelets and megakaryocytes: the present and the future**  
*Alan Nurden (Bordeaux, France)*

16:45-17:15 **Platelets, adenine nucleotides and inflammation**  
*Paolo Gresele (Perugia, Italy)*

17:15-17:45 **The function of CLEC-2 in platelets**  
*Steve Watson (Birmingham, UK)*

17:45-18:15 **Platelets and diabetes**  
*Giovanni Davi (Chieti, Italy)*



## PROGRAM

Thursday, September 2, 2010

**18:30-19:15** **Oral Communications**

Chairperson: *Raimondo De Cristofaro (Roma, Italy)*

18:30-18:45 **MEGAKARYOCYTES POSSESS A FUNCTIONAL INTRINSIC APOPTOSIS PATHWAY, BUT DO NOT USE IT TO PRODUCE PLATELETS**

James C<sup>1,8</sup>, Josefsson EC<sup>1</sup>, Henley KJ<sup>1</sup>, Debrincat MA<sup>1</sup>, Rogers KL<sup>5</sup>, Dowling MR<sup>6</sup>, White MJ<sup>1</sup>, Kruse EA<sup>1</sup>, Ellis S<sup>7</sup>, Nurden P<sup>8</sup>, Vandenberg C<sup>2</sup>, Mason KD<sup>2</sup>, O'Reilly LA<sup>2</sup>, Metcalf D<sup>3</sup>, Roberts AW<sup>3</sup>, Huang DCS<sup>4</sup>, and Kile BT<sup>1</sup>

<sup>1</sup>Molecular Medicine Division; <sup>2</sup>Molecular Genetics of Cancer Division; <sup>3</sup>Cancer and Hematology Division; <sup>4</sup>Chemical Biology; <sup>5</sup>Advanced Research Technologies; <sup>6</sup>Immunology Division, The Walter and Eliza Hall Institute of Medical Research, Parkville 3052, Australia; <sup>7</sup>Peter MacCallum Cancer Centre, St. Andrew's Place, East Melbourne 3002, Australia; <sup>8</sup>Centre de Référence des Pathologies Plaquettaires, Hôpital Haut Lévêque, 33604 Pessac, France

18.45-19:00 **PATTERNED HYDROGELS FOR CONTROLLED PLATELET ADHESION FROM WHOLE BLOOD AND PLASMA**

Lars Faxälv<sup>1</sup>, Tobias Ekblad<sup>2</sup>, Olof Andersson<sup>2</sup>, Nanny Wallmark<sup>2</sup>, Andréas Larsson<sup>2</sup>, Tomas L. Lindahl<sup>1</sup> and Bo Liedberg<sup>2</sup>

<sup>1</sup>Division of Clinical Chemistry, Department of Clinical and Experimental Medicine, Linköping University, SE-581 85 Linköping (Sweden); <sup>2</sup>Division of Molecular Physics, Department of Physics, Chemistry and Biology, Linköping University, SE-581 83 Linköping (Sweden)

19:00-19:15 **PLATELETS SECRETE DIFFERENT SUBSTANCES FROM DIFFERENT  $\alpha$ -GRANULES, WITH ABILITY TO SYNTHESISE NEW PROTEINS**

Martina Nylander<sup>1</sup>, Emma Löfgren<sup>1</sup> and Tomas L. Lindahl<sup>1</sup>

<sup>1</sup>Department of Clinical Chemistry, University Hospital, Linköping, Sweden



## PROGRAM

Friday, September 3, 2010

**08:00-10:30** **SESSION 3**  
**"ANTIPLATELET DRUGS: NEW TARGETS"**

Chairpersons: *Giovanni de Gaetano (Campobasso, Italy)*  
*Elena Tremoli (Milano, Italy)*

08:00-08:30 **VWF/GPIIb axis**  
*Hans Deckmyn (Leuven, Belgium)*

08:30-09:00 **P2Y1**  
*Christian Gachet (Strasbourg, France)*

09:00-09:30 **GPVI**  
*Martine Jandrot-Perrus (Paris, France)*

09:30-10:00 **PAR-1**  
*Athan Kuliopulos (Boston, USA)*

10:00-10:30 **Syk**  
*Patrick André (San Francisco, USA)*

10:30-11:00 Coffee Break ☕

**11:00-13:00** **SESSION 4**  
**"THE BALANCE BETWEEN EFFICACY**  
**AND SAFETY WITH ANTIPLATELET DRUGS"**

Chairpersons: *Rosanna Abbate (Firenze, Italy)*  
*Fabio Pulcinelli (Roma, Italy)*

11:00-11:30 **Genetic determinants of the**  
**pharmacological response to clopidogrel**  
*Simon Tabassome (Paris, France)*

11:30-12:00 **The bleeding risk in inherited**  
**and drug-induced P2Y12 defects**  
*Marco Cattaneo (Milano, Italy)*

12:00-12:30 **Tests of platelet function for monitoring**  
**antiplatelet therapy: How? When?**  
*David Varon (Tel Aviv, Israel)*

12:30-13:00 **The Varying Effects of Antiplatelet**  
**Agents on In Vivo Platelet Function**  
*Alan D. Michelson (Boston, USA)*



## PROGRAM

Friday, September 3, 2010

**13:00-13:30** **Oral Communications**

Chairperson: *Vincenzo Toschi (Milano, Italy)*

13:00-13:15 **CLINICAL PREDICTORS OF DUAL ASPIRIN**  
**AND CLOPIDOGREL RESISTANCE IN**  
**STABLE CARDIOVASCULAR PATIENTS**  
**FROM THE ADRIE STUDY**

*Pierre Fontana,<sup>1</sup> Philippe Berdagué,<sup>2</sup> Christel Castelli,<sup>3</sup> Séverine Nolli,<sup>1</sup> Isabelle Barazer,<sup>4</sup> Pascale Fabbro-Peray,<sup>3</sup> Jean-François Schved,<sup>5</sup> Henri Bounameaux,<sup>1</sup> François Mach,<sup>6</sup> Philippe de Moerloose,<sup>1</sup> Jean-Luc Reny, MD.<sup>7,8</sup>*

*<sup>1</sup>Division of Angiology and Haemostasis, Geneva University Hospital and Faculty of Medicine, Switzerland, <sup>2</sup>Division of Cardiology, Béziers Hospital, France, <sup>3</sup>BESPIM, Nîmes University Hospital, France, <sup>4</sup>Central laboratories, Béziers Hospital, France, <sup>5</sup>Hematology Laboratory, Montpellier University Hospital, France, <sup>6</sup>Division of Cardiology, Geneva University Hospital, Switzerland, <sup>7</sup>Division of Internal Medicine, Béziers Hospital, France, <sup>8</sup>EA 2992, Montpellier-Nîmes Medical University, France*

13:15-13:30 **GENETIC VARIANTS BESIDES CYP2C19\*2**  
**POLYMORPHISM ARE ASSOCIATED WITH**  
**MAJOR ADVERSE CARDIOVASCULAR**  
**EVENTS IN HIGH RISK VASCULAR**  
**PATIENTS ON DUAL ANTIPLATELET**  
**THERAPY**

*Betti Giusti, Claudia Saracini, Anna Vestrini, Alberto Magi, Rossella Marcucci, Luciana Rossi, Antonella Cordisco, Cristina Nanna, Gian Franco Gensini, Rosanna Abbate*  
*Department of Medical and Surgical Critical Care, University of Florence-Atherothrombotic Diseases, AOU Careggi Department of Heart and Vessel, AOU Careggi*



## PROGRAM

Friday, September 3, 2010

**16:30-19:00**    **SESSION 5**  
**“ACUTE CORONARY SYNDROMES”**

Chairpersons: *Maddalena Lettino (Pavia, Italy)*  
*Stefano Savonitto (Milano, Italy)*

16:30-17:00    **Therapeutic approach to patients with ACS**  
*Robert Storey (Sheffield, UK)*

17:00-17:30    **Thrombin and its inhibition in ACS**  
*Raffaele De Caterina (Chieti, Italy)*

17:30-18:00    **TxA2 and its inhibition in ACS**  
*Francesco Violi (Roma, Italy)*

18:00-18:30    **GPIIb/IIIa and its inhibition in ACS**  
*Kurt Huber (Vienna, Austria)*

18:30-19:00    **P2Y12 and its inhibitor in ACS**  
*Paul Gurbel (Washington, USA)*



## PROGRAM

Friday, September 3, 2010

**19:15-20:00**    **Oral Communications**

Chairperson: *Erica De Candia (Roma, Italy)*

19:15-19:30    **MONITORING PLATELET FUNCTION IN PATIENTS DURING ADMINISTRATION OF CLOPIDOGREL WITH/WITHOUT PROTON PUMP INHIBITORS, AND DURING CLOPIDOGREL WITHDRAWAL**

*Sue Fox, Jane May, Mark Thomas, Yanushi Wijeyeratne, Andrew Johnson, Ann White, Natalia Dovlatova, Ashish Shah, Stan Heptinstall*  
*Cardiovascular Medicine, University of Nottingham, Nottingham, UK*

19:30-19:45    **PRACTICAL USE AND LIMITATIONS OF ADP AGGREGATION TESTING TO PREDICT CARDIOVASCULAR EVENTS: DESIGN AND PRELIMINARY RESULTS OF A META-ANALYSIS ON INDIVIDUAL PATIENTS DATA**

By the CLOpidorel, Vascular ISchemic events and biological response Meta-Analysis Group-CLOVIS-MAG:

*Reny JL<sup>1</sup>, Fontana P<sup>1</sup>, Fabbro-Peray P<sup>2</sup>, Laporte S<sup>3</sup>, van Werkum JW<sup>4</sup>, Ten Berg JM<sup>4</sup>, Geisler T<sup>5</sup>, Gawaz M<sup>6</sup>, Gurbel PA<sup>6</sup>, Alessi MC<sup>7</sup>, Yong G<sup>8</sup>, Angiolillo DJ<sup>9</sup>, Campo G<sup>10</sup>, Combescure C<sup>1</sup>.*

*<sup>1</sup>Geneva University Hospital, Clinical Epidemiology-Hemostasis-Angiology-Internal Medicine Switzerland; <sup>2</sup>BESPIM, Nîmes University Hospital, France; <sup>3</sup>GRT, EA3075, Saint-Etienne University Hospital, France; <sup>4</sup>St Antonius Hospital, Nieuwegein, The Netherlands; <sup>5</sup>University Hospital Tübingen, Germany; <sup>6</sup>Sinai Center for Thrombosis Research, Baltimore, USA; <sup>7</sup>Marseilles University Hospitals, France; <sup>8</sup>Royal Perth Hospital, Australia; <sup>9</sup>University of Florida College of Medicine-Jacksonville, USA; <sup>10</sup>Cardiovascular Institute, Anna Hospital, Ferrara, Italy*



## PROGRAM

Friday, September 3, 2010

### Oral Communications

- 19:45-20:00 **HIGH-ON TREATMENT PLATELET REACTIVITY BY DIFFERENT STIMULI IS A DETERMINANT OF MORTALITY IN ACUTE CORONARY SYNDROME PATIENTS: DATA FROM AMI-FLORENCE 2 STUDY**  
Marcucci R, Giusti B, Gori AM, Paniccia R, Cordisco A, Balzi D, Santoni R, Bagnoli L, Abbate R, Gensini GF  
*Dipartimento Area Critica Medico Chirurgica, Università di Firenze*



## PROGRAM

Saturday, September 4, 2010

Chairpersons: *Felicita Andreotti (Roma, Italy)*  
*Giovanni Di Minno (Napoli, Italy)*

### 08:30-11:00 SESSION 6 "OLD AND NEW P2Y12 INHIBITORS"

- 08:30-09:00 **Clopidogrel**  
*Giuseppe Di Pasquale (Bologna, Italy)*
- 09:00-09:30 **Prasugrel**  
*Stefano De Servi (Legnano, Italy)*
- 09:30-10:00 **Ticagrelor**  
*Diego Ardissino (Parma, Italy)*
- 10:00-10:30 **Cangrelor**  
*Robert Storey (Sheffield, UK)*
- 10:30-11:00 **Elinogrel**  
*Pamela Conley (San Francisco, USA)*
- 11:00-11:30 Coffee Break ☕

### 11:30-12:30 Oral Communications

Chairpersons: *Marco Cattaneo (Milano, Italy)*  
*Christian Gachet (Strasbourg, France)*

- 11:30-11:45 **CHARACTERISTICS OF PLATELET FUNCTION IN STABLE ASPIRIN-TREATED CARDIOVASCULAR PATIENTS**  
A. Zufferey<sup>1,2</sup>, J.-L. Remy<sup>3</sup>, S. Nolli<sup>1</sup>, C. Combescure<sup>4</sup>, J. Mascarini<sup>1</sup>, P. de Moerloose<sup>1</sup>, J.-C. Sanchez<sup>2</sup>, P. Fontana<sup>1</sup>  
*<sup>1</sup>Division of Angiology and Haemostasis, <sup>2</sup>Biomedical Proteomics Research Group, Structural Biology and Bioinformatics Department, <sup>3</sup>Division of General Internal Medicine, <sup>4</sup>Division of Clinical Epidemiology, Geneva University Hospital and Faculty of Medicine, Switzerland*



## PROGRAM

**Saturday, September 4, 2010**

### Oral Communications

- 11:45-12:00 **DOES ADENOSINE DERIVED FROM ADP BREAKDOWN CONTRIBUTE TO INHIBITION OF PLATELET AGGREGATION IN THE PRESENCE OF A P2Y<sub>12</sub> ANTAGONIST?**  
David Iyú\*, Jackie R Glenn, Ann E White, Sue C Fox, and Stan Heptinstall  
*Cardiovascular Medicine, Queen's Medical Centre, University of Nottingham, UK*
- 12:00-12:15 **MODE OF ACTION OF P2Y<sub>12</sub> ANTAGONISTS AS INHIBITORS OF PLATELET FUNCTION**  
David Iyú\*, Jackie R. Glenn, Ann E. White, Sue C. Fox, Hans van Giezen\*, Sven Nylander\*, and Stan Heptinstall  
*Cardiovascular Medicine, Queen's Medical Centre, University of Nottingham, Nottingham, UK and \*Department of Bioscience, Astra Zeneca R&D Mölndal, Mölndal, Sweden*
- 12:15-12:30 **VARIABLE EFFECT OF P2Y<sub>12</sub> INHIBITION ON PLATELET THROMBUS VOLUME IN FLOWING BLOOD**  
Mendolicchio G. Loredana, MD, PhD,<sup>1,2</sup> Zavalloni Dennis, MD,<sup>3</sup> Bacci Monica, BSc,<sup>1</sup> Corrada Elena, MD,<sup>4</sup> Marconi Manuel, MD,<sup>4</sup> Lodigiani Corrado, MD,<sup>1</sup> Presbitero Patrizia, MD,<sup>3</sup> Rota Lidia, MD,<sup>1</sup> Ruggeri Zaverio M., MD.<sup>5</sup>  
*<sup>1</sup>Thrombosis Center, <sup>2</sup>Laboratory of Quantitative Medicine, <sup>3</sup>Invasive Cardiology Unit, <sup>4</sup>Cardiac Care Unit, IRCCS Istituto Clinico Humanitas, Rozzano, Milan, Italy; <sup>5</sup>Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, United States*



## SCIENTIFIC INFORMATION

### PROJECTIONS

PC Power Point (no Macintosh).

Power Point presentations must be handed in at the "Projection center" at least one hour before the beginning of the session.

### OFFICIAL LANGUAGE

The official language of the Meeting is English.

### CONTINUING MEDICAL EDUCATION

Credits for C.M.E. program have been requested to the Italian Ministry of Health. The Meeting has received 7 credits for medical doctors and biologists.



